Relay Therapeutics Boosts Price Target Amid Trial Progress
H.C. Wainwright has enhanced its outlook for Relay Therapeutics (NASDAQ: RLAY), increasing the price target to $19.00 from the previous $18.00 while keeping a Buy rating intact. This positive shift follows promising updates regarding the company’s Phase 1 ReDiscover trial, which is focused on RLY-2608—a potential treatment for PiK3CA-mutant, HR+/HER2- metastatic breast cancer.
Impressive Outcomes from the RLY-2608 Trial
Recent findings reveal that the combination of RLY-2608 and Faslodex has produced strong results. At the recommended phase 2 dose, the duo showed a notable 33.3% objective response rate (ORR) and a median progression-free survival (mPFS) of 9.2 months across 64 patients. For those with kinase mutations, the results were even more encouraging, with an ORR of 53% and an mPFS of 10.3 months.
RLY-2608's Safety Profile
Assessing RLY-2608's safety profile is crucial, revealing that only 1.6% of patients experienced Grade 3 or higher hyperglycemia. Moreover, most of the hyperglycemia cases were graded as mild (Grade 1) and generally did not require intervention, indicating good tolerability for patients.
Next Steps in Clinical Trials
Following the encouraging trial data, Relay Therapeutics is set to kick off a pivotal trial in 2025. This upcoming study will compare the effects of RLY-2608 combined with Faslodex against Truqap (capivasertib) paired with Faslodex, using mPFS as the primary measure of effectiveness.
Adjusted Approval Chances for RLY-2608
In light of the trial updates, H.C. Wainwright has increased the likelihood of RLY-2608 gaining approval in combination with Faslodex, raising it from 25% to 60%. However, they've also lowered the expected peak market penetration rate from 20% to 15%. This adjustment reflects both the promising trial results and the impact of a recent equity raise by Relay Therapeutics.
Analyst Perspectives
In recent months, analysts have taken a closer look at Relay Therapeutics, leading to various adjustments. Stifel has maintained its Buy rating with a price target of $28.00, while Jefferies has upgraded its rating from Hold to Buy after receiving positive interim data. On the flip side, Oppenheimer has lowered its outlook from Outperform to Perform due to concerns surrounding RLY-2608's selectivity profile.
Focus on Growth and Market Presence
Goldman Sachs has re-evaluated Relay Therapeutics, reinstating coverage with a Buy rating and setting a target price of $20.00. Despite revising its target down to $18.00, H.C. Wainwright continues to advocate for a Buy stance.
Financial Position Overview
Recently, Relay Therapeutics initiated a $200 million underwritten public offering to strengthen its financial position. Major financial firms, including Goldman Sachs & Co. LLC, TD Cowen, and Stifel, are acting as joint book-running managers for this offering. By the second quarter of 2024, Relay reported around $688 million in cash, which is projected to support its operations through 2026, indicating solid sustainability.
Investors' Perspective and Market Trends
As Relay Therapeutics (NASDAQ: RLAY) progresses in its clinical endeavors, investors should closely monitor both scientific breakthroughs and financial performance. Current insights show that Relay has more cash than debt, enhancing its financial stability. Additionally, upward adjustments by four analysts regarding future earnings give a positive outlook on Relay’s prospects.
Market Capitalization and Earnings Forecast
With a market cap of $1.23 billion, Relay Therapeutics has reported astonishing revenue growth of over 3637% in the past year. However, it hasn’t yet turned a profit, registering a negative gross profit margin of approximately -837%. Despite facing volatility, including a significant 20% drop in recent weeks, Relay has achieved nearly an 18% return over the last month.
Upcoming Earnings Release
The next earnings announcement is set for October 31, 2024, and is expected to be a crucial moment for investors wanting to assess Relay’s future financial trajectory.
Frequently Asked Questions
What recent updates have influenced Relay Therapeutics' stock target?
H.C. Wainwright raised the stock's target to $19.00 after promising results from the ReDiscover trial involving RLY-2608.
What are the main findings from the Phase 1 ReDiscover trial?
The trial showed a 33.3% objective response rate and a median progression-free survival of 9.2 months with RLY-2608 combined with Faslodex.
What is the safety profile of RLY-2608?
RLY-2608 demonstrated a favorable safety profile, with only 1.6% of patients experiencing severe hyperglycemia.
What financial position does Relay Therapeutics hold?
The company reported approximately $688 million in cash, providing financial stability through 2026.
When is the next earnings report for Relay Therapeutics?
The next earnings report is scheduled for October 31, 2024, marking an important event for investors.
